External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer
Abiraterone acetate is approved for the treatment of castration-resistant prostate cancer (CRPC); however, its effects vary. An accurate prediction model to identify patient groups that will benefit from abiraterone treatment is therefore urgently required. The Chi model exhibits a good profile for...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
Series: | Asian Journal of Andrology |
Subjects: | |
Online Access: | http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=2;spage=184;epage=188;aulast=Yang |